Rapamycin Side Effects: What Studies Report

What "side effects" means in the rapamycin literature

Rapamycin, also known as sirolimus, is a macrolide compound that inhibits the mechanistic target of rapamycin (mTOR). A 2022 pharmacology review of mTOR inhibitors described the class-level adverse-effect profile as including stomatitis and mucosal ulceration, dyslipidaemia, raised blood glucose and new-onset diabetes, cytopenias, impaired wound healing, proteinuria, peripheral oedema, non-infectious pneumonitis and increased susceptibility to infection (PMID 35091825). Those findings did not all appear at the same frequency in every study, because the compound has been investigated at very different exposures — from continuous daily immunosuppressive dosing to intermittent weekly regimens — and a 2022 overview of clinical trials targeting aging noted that the field's safety data come from heterogeneous populations and trial designs rather than from one uniform evidence base (PMID 35821843).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, symptom or laboratory result. It summarises what researchers recorded in published papers and does not describe a regimen for any individual.

Three very different exposure contexts

• Solid-organ transplantation. A 2021 review of long-term immunosuppression management discussed mTOR inhibitors alongside other agents and framed chronic therapy as a balance between rejection on one side and infection, malignancy and drug-specific toxicity on the other, with therapeutic drug monitoring used to manage that balance (PMID 33853841).
• Rare disease and paediatric neurology. A 2024 phase I study reported on preventative sirolimus in tuberous sclerosis complex and was designed primarily around safety and tolerability endpoints in a young population (PMID 39726432), while a 2022 review of lymphangioleiomyomatosis noted that concerns about systemic sirolimus exposure have motivated interest in localised delivery approaches (PMID 35043744).
• Ageing-focused research. A 2024 systematic review of rapamycin and its derivatives in humans assembled trials conducted with ageing-related endpoints and reported that the adverse events documented in that literature were predominantly mild and reversible, with no consistent signal of serious harm in the short-duration studies reviewed (PMID 38310895).

Mucosal and oral effects: What Studies Report

Mouth ulceration is among the most frequently discussed effects in the mTOR inhibitor literature. The 2022 pharmacology review listed stomatitis and aphthous-type mucosal lesions as characteristic adverse effects of the drug class, describing them as dose-related and typically managed by dose adjustment or interruption in clinical practice (PMID 35091825). The 2024 systematic review of rapamycin in humans similarly placed mild, self-limited events of this kind among the events recorded in ageing-related trials rather than among the events that led to study discontinuation (PMID 38310895). Dermatological reports have also described rapamycin in inflammatory skin disease, including a 2018 report on refractory discoid lupus erythematosus that documented treatment course and tolerability in that setting (PMID 30109759).

Metabolic and lipid changes: What Studies Report

Changes in lipids and glucose handling recur across the literature. The 2022 review described hypertriglyceridaemia, hypercholesterolaemia, insulin resistance and new-onset diabetes after transplantation as recognised metabolic consequences of mTOR inhibition (PMID 35091825). The 2021 immunosuppression review discussed routine laboratory surveillance of metabolic and cardiovascular risk factors as part of long-term management of transplant recipients receiving maintenance therapy (PMID 33853841). In the ageing-focused literature, the 2024 systematic review reported that biochemical parameters were monitored across included trials and that the metabolic shifts observed at lower or intermittent exposures were generally smaller than those described in chronic transplant dosing (PMID 38310895).

Infection and immune-related findings: What Studies Report

Because rapamycin is an immunosuppressant, infection risk is a central theme. The 2021 review described infection and malignancy as the principal long-term hazards of sustained immunosuppression in transplant recipients and discussed minimisation strategies and monitoring intended to reduce that burden (PMID 33853841), and the 2022 pharmacology review likewise listed increased infection susceptibility among the class effects of mTOR inhibitors (PMID 35091825). Findings differed in lower-exposure research: in the PEARL trial, which randomised healthy middle-aged and older adults to 5 mg or 10 mg of compounded rapamycin weekly or placebo for 48 weeks, researchers reported that adverse event frequency — including infections — did not differ significantly between the rapamycin and placebo groups (PMID 40188830). The 2024 systematic review cautioned that most ageing-focused trials were short and modestly sized, which limits what they can say about infection risk over years of exposure (PMID 38310895).

Blood counts, kidney and lung findings: What Studies Report

The 2022 pharmacology review described cytopenias — including anaemia, leucopenia and thrombocytopenia — proteinuria and non-infectious interstitial pneumonitis among the adverse effects documented with mTOR inhibitor therapy, noting that pneumonitis, although uncommon, has been treated as a reason for drug discontinuation in clinical reports (PMID 35091825). The 2021 immunosuppression review discussed the way proteinuria and graft function influence agent selection and dose adjustment in kidney transplant recipients over long follow-up (PMID 33853841).

Wound healing and procedural context: What Studies Report

Impaired wound healing and lymphocele formation were described in the 2022 review as recognised perioperative concerns with mTOR inhibitors, which is one reason the review discussed timing of these agents around surgery in transplant care (PMID 35091825). The 2021 review addressed the same issue within the broader question of how maintenance regimens are sequenced and modified after transplantation (PMID 33853841).

What randomised and prospective trials outside transplantation reported

A 2023 randomised, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis administered the drug over an 18-week treatment period and reported that treatment was tolerated without unexpected safety findings, although the trial did not demonstrate benefit on its primary clinical outcome (PMID 37591957). In the PEARL trial, the study randomised healthy adults to weekly 5 mg or 10 mg rapamycin or placebo for 48 weeks and evaluated safety alongside healthspan-related measures, with researchers reporting no significant increase in adverse events attributable to the drug over that period (PMID 40188830). The 2024 phase I study of preventative sirolimus in tuberous sclerosis complex reported safety and efficacy results from a young cohort, a population in which prospective tolerability data had previously been scarce (PMID 39726432).

Continuous versus intermittent exposure in the literature

A recurring argument in the field is that schedule, not just total amount, shapes the adverse-event picture. A 2019 opinion article on rapamycin and longevity argued that the effects observed with continuous high-dose immunosuppressive use should not be assumed to apply to intermittent, lower-exposure schedules, and proposed that intermittency was the mechanism by which many of those effects might be avoided (PMID 31586989). The 2024 systematic review examined this question empirically and reported that the ageing-focused trials it included had largely used lower or intermittent regimens and had documented mostly mild adverse events, while also stating that the available trials were too short and too small to settle long-term safety (PMID 38310895).

Self-reported experience in off-label use: What Studies Report

A 2023 evaluation examined off-label rapamycin use for healthspan purposes among 333 adults and collected self-reported adverse events alongside perceived health measures, with researchers reporting that the events described by respondents were generally mild and self-limited rather than serious (PMID 37191826). That paper was survey-based rather than randomised, so the authors' framing emphasised description of a self-selected group instead of causal inference (PMID 37191826). Reviews of the wider trial landscape have made a similar point about the need for controlled, longer-duration data before adverse-event frequencies can be stated with confidence (PMID 35821843).

Localised delivery research

Part of the preclinical literature is explicitly motivated by systemic tolerability. A 2022 review of prospective nanoparticle treatments for lymphangioleiomyomatosis discussed delivery systems intended to concentrate sirolimus at the target tissue and reduce systemic exposure (PMID 35043744). A 2021 laboratory study prepared and characterised rapamycin-loaded poly(lactic-co-glycolic acid) nanoparticles and included an in vitro toxicity assessment relevant to potential intra-articular injection (PMID 34662644). Those were formulation and cell-based studies, not human safety trials, and their findings do not translate directly into clinical adverse-event rates (PMID 34662644).

How researchers described monitoring

Across clinical settings, the papers describe surveillance rather than a fixed checklist. The 2021 immunosuppression review discussed therapeutic drug monitoring, infection screening and laboratory follow-up as standard components of long-term care in transplant recipients (PMID 33853841). The 2022 pharmacology review connected specific monitoring to specific known effects, such as lipid panels for dyslipidaemia and blood counts for cytopenias (PMID 35091825). Trials outside transplantation also built safety monitoring into their protocols, as in the 48-week PEARL design, where the study tracked adverse events and laboratory measures over the full treatment period (PMID 40188830).

Limits of the current evidence

• Duration. The 2024 systematic review reported that ageing-focused human trials of rapamycin and rapalogs were mostly short, leaving multi-year safety largely uncharacterised (PMID 38310895).
• Population mismatch. Much of the detailed adverse-event data comes from transplant and oncology contexts, where dosing, comorbidity and concomitant drugs differ from healthy-volunteer research (PMID 33853841).
• Design heterogeneity. The 2022 review of trials targeting aging described substantial variation in endpoints and methods across the field, which complicates pooling of safety results (PMID 35821843).
• Self-report bias. The 2023 off-label evaluation of 333 adults relied on participant-reported outcomes, which the authors treated as descriptive rather than definitive (PMID 37191826).

Taken together, the published record describes a well-catalogued set of dose-related effects at immunosuppressive exposures and a comparatively quiet short-term profile in the lower-exposure trials conducted so far, with researchers in both camps calling for longer controlled follow-up before firm conclusions are drawn (PMID 38310895).

References

• Mechanistic Target of Rapamycin (mTOR) Inhibitors (Handbook of Experimental Pharmacology, 2022)
• Long-Term Immunosuppression Management: Opportunities and Uncertainties (CJASN, 2021)
• Targeting ageing with rapamycin and its derivatives in humans: a systematic review (The Lancet Healthy Longevity, 2024)
• Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results (Aging, 2025)
• Evaluation of off-label rapamycin use to promote healthspan in 333 adults (GeroScience, 2023)
• Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis (Nature Communications, 2023)
• Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results (Annals of the Child Neurology Society, 2024)
• Rapamycin for longevity: opinion article (Aging, 2019)
• Clinical Trials Targeting Aging (Frontiers in Aging, 2022)
• Prospective nanoparticle treatments for lymphangioleiomyomatosis (Expert Opinion on Drug Delivery, 2022)
• Rapamycin-loaded Poly(lactic-co-glycolic) acid nanoparticles: Preparation, characterization, and in vitro toxicity study for potential intra-articular injection (International Journal of Pharmaceutics, 2021)
• Rapamycin for refractory discoid lupus erythematosus (Dermatologic Therapy, 2018)